<?xml version="1.0" encoding="UTF-8"?>
<p>There was no significant difference in the plasma concentration–time curve following intragastric administration of ETV to normal and DMN-induced hepatic fibrosis rats (
 <xref ref-type="fig" rid="F0004">Figure 4(B)</xref>). Furthermore, there were no significant differences in the pharmacokinetic parameters of ETV (
 <italic>C</italic>
 <sub>max</sub>, 
 <italic>T</italic>
 <sub>max</sub>, AUC
 <sub>0–</sub>
 <italic>
  <sub>t</sub>
 </italic>, AUC
 <sub>0–∞</sub>, MRT and CL) measured under the normal physiological and pathological conditions (
 <xref rid="t0002" ref-type="table">Table 2</xref>). However, in the ETV-M groups, the 
 <italic>t</italic>
 <sub>1/2e</sub> and 
 <italic>V</italic>
 <sub>d</sub>/
 <italic>F</italic> were increased significantly to 8.01 ± 1.30 h (
 <italic>p</italic> &lt; 0.01) and 24.38 ± 9.10 L/kg (
 <italic>p</italic> &lt; 0.05) compared with that of the ETV-N group, respectively. Otherwise, in the EF-M-2 group, the 
 <italic>t</italic>
 <sub>1/2e</sub> (7.91 ± 1.89 h) and MRT (7.40 ± 1.51 h) values were increased compared with that of the ETV-N group. The ETV plasma concentration–time curve in the EF-M-2 group rats was similar to that in the ETV-M group. Although the 
 <italic>C</italic>
 <sub>max</sub> of ETV was significantly lower (76.54 ± 36.16 μg/L) in model rats compared with that in normal rats (127.72 ± 29.48 μg/L, 
 <italic>p</italic> &lt; 0.05
 <italic>)</italic> and its 
 <italic>T</italic>
 <sub>max</sub> was more rapid (
 <italic>p</italic> &lt; 0.05
 <italic>)</italic>, there were no significant differences in other parameters.
</p>
